Sign in

CIK 0001321834

  • Non-accelerated filer
  • Smaller reporting company

Q/C TECHNOLOGIES, INC.

Sign in to watch
Ticker
QCLS
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 856-848-8698
Business address
1185 AVENUE OF THE AMERICAS, SUITE 249, NEW YORK, NY, 10036
Former names
Q/C TECHNOLOGIES, INC., TNF Pharmaceuticals, Inc., MyMD Pharmaceuticals, Inc., Akers Biosciences, Inc., Akers Biosciences Inc
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award President, Chief Med. Officer acquired 96,475 shares (grant or award)
  3. 3 Insider Initial Statement of Ownership
  4. 3 Insider Initial Statement of Ownership
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Shares withheld for taxes Director gave up 14,694 shares (to pay taxes)
  8. 4 Shares withheld for taxes Director gave up 38,325 shares (to pay taxes)
  9. 4 Shares withheld for taxes Director gave up 38,325 shares (to pay taxes)
  10. 3 Insider Initial Statement of Ownership
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale 10% owner sold 638 shares at $2.81 ($1,793)
  17. 4 Open-market sale 10% owner sold 28,300 shares at an average $2.81 ($79,576)
  18. 4 Open-market buy 10% owner bought 184,578 shares at an average $3.01 ($555,550)
  19. 3 Insider Initial Statement of Ownership
  20. 4 Option exercise Executive Chairman acquired 5,201 shares (option exercise)

Page 4 of 7 · 132 filings